RECORD // Company

Galectin Therapeutics Inc

Formerly: PRO PHARMACEUTICALS INC

Built 2026-11-22T00:54:34Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Galectin Therapeutics Inc. · Ctgov · same registered legal name as 'GALECTIN THERAPEUTICS INC' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001140361-26-043988

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-3,531,0003 months ended 2026-09-3010-Q2026-11-160001140361-26-0439882026-11-22 00:54 UTCReport an error
Interest expense$786,0003 months ended 2026-09-3010-Q2026-11-160001140361-26-0439882026-11-22 00:54 UTCReport an error
Cash and cash equivalents$11,706,000at 2026-09-3010-Q2026-11-160001140361-26-0439882026-11-22 00:54 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001133416
Ticker
GALT
EIN
043562325
CUSIP
363225202
Record ID
sx:sec:0001133416

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

30 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:54 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:54 UTCReport an error
State of incorporationNV2026-11-16SEC EDGAR company profile2026-11-22 00:54 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:54 UTCReport an error
Business address4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 300712026-11-16SEC EDGAR company profile2026-11-22 00:54 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:54 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-30,836,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:54 UTCReport an error
Total assets (at 2025-12-31)$19,532,0002025-12-3110-K, XBRL Assets2026-11-22 00:54 UTCReport an error
Stockholders' equity (at 2025-12-31)$-127,918,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:54 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$17,720,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:54 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-23,875,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:54 UTCReport an error
Operating lease liabilities (at 2025-12-31)$22,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:54 UTCReport an error
Form D total offering amount (D filed 2017-01-06)$10,000,0002017-01-06D2026-11-22 00:54 UTCReport an error
Form D total amount sold (D filed 2017-01-06)$3,000,0002017-01-06D2026-11-22 00:54 UTCReport an error
Form D industry groupPharmaceuticals2017-01-06D2026-11-22 00:54 UTCReport an error
Form D revenue rangeDecline to Disclose2017-01-06D2026-11-22 00:54 UTCReport an error
Form D date of first sale2016-12-222017-01-06D2026-11-22 00:54 UTCReport an error
8-K Item 2.02 (filed 2026-11-16)Results of Operations and Financial Condition. On November 16, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended September 30, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 16, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward-looking statements that involve risks and uncertainties. All such statements are subject…2026-11-16SEC EDGAR 8-K 0001140361-26-043989 (text as filed, excerpt)2026-11-22 00:54 UTCReport an error
8-K Item 2.02 (filed 2026-08-14)Results of Operations and Financial Condition. On August 14, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward-looking statements that involve risks and uncertainties. All such statements are subject to the…2026-08-14SEC EDGAR 8-K 0001140361-26-032946 (text as filed, excerpt)2026-11-22 00:54 UTCReport an error
8-K Item 3.02 (filed 2026-08-04)Unregistered Sales of Equity Securities.. On July 31, 2026, Galectin Therapeutics Inc. (the "Company") issued 34,376,167 shares of its common stock, par value $0.001 per share (the "Common Stock"), to Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, upon the conversion of all outstanding convertible promissory notes (the "Notes") issued to Mr. Uihlein under the following line of credit facilities: (i) the Line of Credit Letter Agreement dated July 25, 2022 (providing for a $60,000,000 credit facility); (ii) the Supplemental Line of Credit Agreement dated March 29, 2024 (providing for a $10,000,000 supplemental credit facility); (iii) the November 2024…2026-08-04SEC EDGAR 8-K 0001140361-26-031058 (text as filed, excerpt)2026-11-22 00:54 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$13,865,9572026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #2 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$10,059,8222026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #3 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$6,072,5092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #4 (13F as filed): OSAIC HOLDINGS, INC.$5,585,2802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #5 (13F as filed): MARSHALL WACE, LLP$3,855,8882026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #6 (13F as filed): Wealthspire Advisors, LLC$3,349,0972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #7 (13F as filed): STATE STREET CORP$2,634,4952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #8 (13F as filed): COMMONWEALTH EQUITY SERVICES, LLC$1,889,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #9 (13F as filed): NORTHERN TRUST CORP$1,793,5692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD FIDUCIARY TRUST CO$1,700,4492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:54 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.